HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
10/6/2026
Impact: 70
Healthcare
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Korro Bio (NASDAQ: KRRO) and maintained a price target of $15 for the stock.
AI summary, not financial advice
Share: